Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 27 | 2023 | 2134 | 3.110 |
Why?
|
| Botswana | 29 | 2023 | 87 | 1.980 |
Why?
|
| Malaria Vaccines | 1 | 2022 | 20 | 0.880 |
Why?
|
| Malaria | 1 | 2022 | 92 | 0.830 |
Why?
|
| HIV Seropositivity | 1 | 2022 | 144 | 0.800 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2020 | 20 | 0.760 |
Why?
|
| Food Supply | 1 | 2014 | 97 | 0.470 |
Why?
|
| Genomics | 5 | 2023 | 2738 | 0.410 |
Why?
|
| Pharmacogenetics | 2 | 2023 | 260 | 0.410 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2023 | 247 | 0.340 |
Why?
|
| Child | 20 | 2023 | 29154 | 0.320 |
Why?
|
| Adolescent | 22 | 2023 | 31252 | 0.290 |
Why?
|
| Anti-HIV Agents | 2 | 2023 | 350 | 0.290 |
Why?
|
| Africa South of the Sahara | 5 | 2023 | 101 | 0.260 |
Why?
|
| Mental Disorders | 2 | 2023 | 862 | 0.250 |
Why?
|
| Disclosure | 2 | 2023 | 181 | 0.250 |
Why?
|
| Feedback | 5 | 2022 | 198 | 0.240 |
Why?
|
| Wolves | 1 | 2023 | 4 | 0.230 |
Why?
|
| Counselors | 1 | 2023 | 18 | 0.230 |
Why?
|
| Thinness | 1 | 2023 | 82 | 0.230 |
Why?
|
| Humans | 42 | 2023 | 261506 | 0.230 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2022 | 297 | 0.220 |
Why?
|
| Dog Diseases | 1 | 2023 | 73 | 0.220 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2022 | 43 | 0.220 |
Why?
|
| Self-Injurious Behavior | 1 | 2023 | 54 | 0.210 |
Why?
|
| International Educational Exchange | 1 | 2022 | 17 | 0.210 |
Why?
|
| Social Stigma | 1 | 2022 | 73 | 0.210 |
Why?
|
| Anti-Retroviral Agents | 3 | 2023 | 148 | 0.210 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2021 | 25 | 0.200 |
Why?
|
| Thrombocytosis | 1 | 2022 | 121 | 0.200 |
Why?
|
| Chloroquine | 1 | 2021 | 53 | 0.200 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2021 | 16 | 0.200 |
Why?
|
| Nicotine | 1 | 2023 | 244 | 0.200 |
Why?
|
| Hydroxychloroquine | 1 | 2021 | 32 | 0.200 |
Why?
|
| Immune Evasion | 1 | 2022 | 73 | 0.200 |
Why?
|
| Patient Compliance | 2 | 2016 | 667 | 0.200 |
Why?
|
| Suicide | 1 | 2023 | 180 | 0.190 |
Why?
|
| Qualitative Research | 1 | 2023 | 556 | 0.190 |
Why?
|
| Brain Concussion | 1 | 2023 | 194 | 0.190 |
Why?
|
| Pregnancy | 6 | 2023 | 7573 | 0.190 |
Why?
|
| Dyslipidemias | 1 | 2023 | 235 | 0.190 |
Why?
|
| Oxazines | 1 | 2020 | 43 | 0.190 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2022 | 234 | 0.190 |
Why?
|
| Child, Orphaned | 1 | 2020 | 18 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 362 | 0.180 |
Why?
|
| Safe Sex | 1 | 2019 | 19 | 0.170 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2020 | 146 | 0.170 |
Why?
|
| Malnutrition | 1 | 2022 | 218 | 0.170 |
Why?
|
| Mothers | 1 | 2022 | 410 | 0.170 |
Why?
|
| Research Personnel | 1 | 2020 | 156 | 0.170 |
Why?
|
| Motivation | 1 | 2022 | 499 | 0.170 |
Why?
|
| School Health Services | 1 | 2019 | 109 | 0.160 |
Why?
|
| Adaptation, Psychological | 1 | 2023 | 764 | 0.160 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 419 | 0.160 |
Why?
|
| Mental Health | 1 | 2021 | 415 | 0.160 |
Why?
|
| Informed Consent | 1 | 2021 | 419 | 0.160 |
Why?
|
| Pyridones | 1 | 2020 | 348 | 0.160 |
Why?
|
| Premature Birth | 1 | 2022 | 407 | 0.160 |
Why?
|
| Pregnancy Complications | 1 | 2022 | 526 | 0.150 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 227 | 0.150 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 846 | 0.150 |
Why?
|
| Genome, Human | 2 | 2023 | 1869 | 0.150 |
Why?
|
| Genetic Research | 3 | 2022 | 63 | 0.150 |
Why?
|
| Cognitive Dysfunction | 1 | 2022 | 333 | 0.150 |
Why?
|
| HIV | 3 | 2023 | 229 | 0.150 |
Why?
|
| Anemia | 1 | 2022 | 689 | 0.140 |
Why?
|
| Self Administration | 1 | 2016 | 50 | 0.140 |
Why?
|
| Atherosclerosis | 1 | 2023 | 935 | 0.130 |
Why?
|
| Phylogeny | 3 | 2023 | 826 | 0.120 |
Why?
|
| Adolescent Behavior | 1 | 2016 | 230 | 0.120 |
Why?
|
| Tuberculosis | 1 | 2020 | 548 | 0.120 |
Why?
|
| Genetic Variation | 2 | 2021 | 2086 | 0.120 |
Why?
|
| Neuropsychological Tests | 3 | 2023 | 1178 | 0.120 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2013 | 9 | 0.110 |
Why?
|
| Adult | 8 | 2023 | 77950 | 0.110 |
Why?
|
| Lamivudine | 2 | 2022 | 28 | 0.110 |
Why?
|
| HIV Protease Inhibitors | 1 | 2013 | 72 | 0.110 |
Why?
|
| Pyrrolidinones | 1 | 2013 | 61 | 0.110 |
Why?
|
| Uganda | 2 | 2023 | 74 | 0.110 |
Why?
|
| Ritonavir | 1 | 2013 | 67 | 0.110 |
Why?
|
| South Africa | 2 | 2022 | 92 | 0.110 |
Why?
|
| Young Adult | 4 | 2023 | 21445 | 0.100 |
Why?
|
| Piperazines | 1 | 2020 | 2101 | 0.100 |
Why?
|
| Risk Factors | 6 | 2023 | 17523 | 0.100 |
Why?
|
| Growth Disorders | 2 | 2023 | 218 | 0.100 |
Why?
|
| Tanzania | 2 | 2021 | 68 | 0.100 |
Why?
|
| Gene Frequency | 2 | 2023 | 1163 | 0.090 |
Why?
|
| Female | 11 | 2023 | 141928 | 0.090 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2022 | 222 | 0.090 |
Why?
|
| Mass Screening | 3 | 2021 | 1509 | 0.080 |
Why?
|
| Infant | 1 | 2022 | 13310 | 0.070 |
Why?
|
| Alleles | 2 | 2023 | 2437 | 0.070 |
Why?
|
| Medication Adherence | 2 | 2021 | 492 | 0.070 |
Why?
|
| Treatment Failure | 2 | 2021 | 1391 | 0.070 |
Why?
|
| Genotype | 2 | 2023 | 4109 | 0.060 |
Why?
|
| Retrospective Studies | 6 | 2023 | 37905 | 0.060 |
Why?
|
| Cytochrome P-450 CYP2A6 | 1 | 2023 | 18 | 0.060 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2023 | 22 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2022 | 9244 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2013 | 1823 | 0.060 |
Why?
|
| Problem Solving | 1 | 2023 | 85 | 0.060 |
Why?
|
| Nevirapine | 1 | 2022 | 17 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2022 | 16273 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2022 | 6100 | 0.050 |
Why?
|
| Maternal Mortality | 1 | 2022 | 77 | 0.050 |
Why?
|
| Stillbirth | 1 | 2022 | 82 | 0.050 |
Why?
|
| Cholesterol, HDL | 1 | 2023 | 341 | 0.050 |
Why?
|
| Male | 7 | 2023 | 123000 | 0.050 |
Why?
|
| Incidental Findings | 1 | 2023 | 272 | 0.050 |
Why?
|
| Platelet Count | 1 | 2022 | 490 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 6009 | 0.050 |
Why?
|
| Dogs | 1 | 2023 | 1155 | 0.050 |
Why?
|
| Income | 1 | 2022 | 222 | 0.050 |
Why?
|
| Ecosystem | 1 | 2021 | 111 | 0.050 |
Why?
|
| Africa | 1 | 2021 | 142 | 0.050 |
Why?
|
| Triglycerides | 1 | 2023 | 603 | 0.050 |
Why?
|
| Counseling | 1 | 2023 | 381 | 0.050 |
Why?
|
| Executive Function | 1 | 2021 | 160 | 0.050 |
Why?
|
| Haplotypes | 1 | 2022 | 856 | 0.050 |
Why?
|
| Cholesterol | 1 | 2023 | 658 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 140 | 0.050 |
Why?
|
| Cholesterol, LDL | 1 | 2023 | 565 | 0.040 |
Why?
|
| Malawi | 1 | 2021 | 378 | 0.040 |
Why?
|
| Recombination, Genetic | 1 | 2022 | 613 | 0.040 |
Why?
|
| Amino Acids | 1 | 2022 | 728 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2022 | 643 | 0.040 |
Why?
|
| Gene Pool | 1 | 2018 | 7 | 0.040 |
Why?
|
| Geography | 1 | 2018 | 140 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2021 | 745 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 218 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 541 | 0.040 |
Why?
|
| Global Health | 1 | 2022 | 657 | 0.040 |
Why?
|
| Genetics, Population | 1 | 2018 | 242 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2022 | 1732 | 0.040 |
Why?
|
| Cognition | 1 | 2023 | 968 | 0.040 |
Why?
|
| Curriculum | 1 | 2022 | 860 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2021 | 1152 | 0.030 |
Why?
|
| Anxiety | 1 | 2023 | 1179 | 0.030 |
Why?
|
| Psychology, Adolescent | 1 | 2014 | 41 | 0.030 |
Why?
|
| Prognosis | 2 | 2022 | 21713 | 0.030 |
Why?
|
| Psychology | 1 | 2014 | 86 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 493 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 4988 | 0.030 |
Why?
|
| Attitude | 1 | 2014 | 159 | 0.030 |
Why?
|
| Darunavir | 1 | 2013 | 3 | 0.030 |
Why?
|
| Raltegravir Potassium | 1 | 2013 | 3 | 0.030 |
Why?
|
| Depression | 1 | 2023 | 1715 | 0.030 |
Why?
|
| Disease Progression | 1 | 2023 | 6682 | 0.030 |
Why?
|
| Social Support | 1 | 2014 | 560 | 0.020 |
Why?
|
| Phenotype | 1 | 2022 | 6295 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2013 | 317 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 3472 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2022 | 8223 | 0.020 |
Why?
|
| Animals | 2 | 2023 | 59536 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 12873 | 0.020 |
Why?
|
| Mutation | 1 | 2022 | 15179 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 14889 | 0.010 |
Why?
|
| Aged | 1 | 2023 | 70117 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2013 | 32848 | 0.010 |
Why?
|